Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Current Deferred Revenue (2016 - 2023)

Dare Bioscience (DARE) has disclosed Current Deferred Revenue for 3 consecutive years, with $205206.0 as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Current Deferred Revenue changed N/A year-over-year to $205206.0, compared with a TTM value of $205206.0 through Sep 2023, changed N/A, and an annual FY2016 reading of $2.5 million, changed N/A over the prior year.
  • Current Deferred Revenue was $205206.0 for Q3 2023 at Dare Bioscience, down from $2.5 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $205206.0 in Q3 2023 and bottomed at $205206.0 in Q3 2023.